|
Name |
3-Hydroxybenzamide
|
Molecular Formula | C7H7NO2 | |
IUPAC Name* |
3-hydroxybenzamide
|
|
SMILES |
C1=CC(=CC(=C1)O)C(=O)N
|
|
InChI |
InChI=1S/C7H7NO2/c8-7(10)5-2-1-3-6(9)4-5/h1-4,9H,(H2,8,10)
|
|
InChIKey |
NGMMGKYJUWYIIG-UHFFFAOYSA-N
|
|
Synonyms |
3-hydroxybenzamide; 618-49-5; benzamide, 3-hydroxy-; 3-Hydroxy-benzamide; 3-hydroxybenzenecarboxamide; CHEMBL419424; NSC-379289; m-hydroxybenzamide; NSC379289; 3-OXIDANYLBENZAMIDE; 75X4NC5TNX; Oprea1_435073; SCHEMBL161861; 3-Hydroxybenzamide, AldrichCPR; DTXSID90321635; ZINC1590754; 3-HYDROXY-BENZOIC ACID,AMIDE; BDBM50068769; MFCD00017572; AKOS000207073; MB00281; SR-4267; NCGC00323509-01; SY004825; DB-008311; CS-0149666; FT-0600531; H1643; EN300-36686; C75901; AB01155218-03; A833450; AE-562/40219001; Z33546460
|
|
CAS | 618-49-5 | |
PubChem CID | 342403 | |
ChEMBL ID | CHEMBL419424 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 137.14 | ALogp: | 0.4 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 63.3 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.603 |
Caco-2 Permeability: | -4.622 | MDCK Permeability: | 0.00001470 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.99 |
Human Intestinal Absorption (HIA): | 0.009 | 20% Bioavailability (F20%): | 0.016 |
30% Bioavailability (F30%): | 0.959 |
Blood-Brain-Barrier Penetration (BBB): | 0.919 | Plasma Protein Binding (PPB): | 47.73% |
Volume Distribution (VD): | 1.027 | Fu: | 67.34% |
CYP1A2-inhibitor: | 0.461 | CYP1A2-substrate: | 0.31 |
CYP2C19-inhibitor: | 0.057 | CYP2C19-substrate: | 0.059 |
CYP2C9-inhibitor: | 0.025 | CYP2C9-substrate: | 0.537 |
CYP2D6-inhibitor: | 0.08 | CYP2D6-substrate: | 0.389 |
CYP3A4-inhibitor: | 0.026 | CYP3A4-substrate: | 0.154 |
Clearance (CL): | 13.151 | Half-life (T1/2): | 0.575 |
hERG Blockers: | 0.068 | Human Hepatotoxicity (H-HT): | 0.089 |
Drug-inuced Liver Injury (DILI): | 0.402 | AMES Toxicity: | 0.01 |
Rat Oral Acute Toxicity: | 0.056 | Maximum Recommended Daily Dose: | 0.011 |
Skin Sensitization: | 0.207 | Carcinogencity: | 0.069 |
Eye Corrosion: | 0.014 | Eye Irritation: | 0.979 |
Respiratory Toxicity: | 0.042 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000665 | 0.543 | D04EYC | 0.405 | ||||
ENC000076 | 0.486 | D0S5LH | 0.372 | ||||
ENC001055 | 0.475 | D0O6IU | 0.364 | ||||
ENC001056 | 0.475 | D07HBX | 0.350 | ||||
ENC000108 | 0.459 | D06NVJ | 0.333 | ||||
ENC000048 | 0.444 | D0X9RY | 0.333 | ||||
ENC000003 | 0.444 | D01WJL | 0.333 | ||||
ENC003374 | 0.432 | D0C4YC | 0.333 | ||||
ENC002426 | 0.432 | D0U5QK | 0.326 | ||||
ENC000756 | 0.410 | D0S2BT | 0.326 |